Doximity (DOCS) Q1 2026: SMB Bookings Double as AI Suite Anchors Third Act
Doximity’s broad-based growth and accelerating AI integration are reshaping its revenue mix, with SMB bookings up 100% and a path to deeper physician workflow engagement. The Pathway acquisition and Scribe rollout mark a decisive pivot toward AI-native clinical tools, positioning DOCS for recurring engagement and future monetization. Management’s guidance remains measured, balancing strong visibility with policy uncertainty, but operational leverage and margin expansion signal a durable business model.
Summary
- AI Suite Drives Workflow Stickiness: New Scribe and Pathway tools deepen daily physician reliance on DOCS.
- SMB and Pharma Upsell Momentum: Agency-led SMB bookings surged 100%, broadening Doximity’s customer base.
- Margin Expansion Maintained Amid Investment: AI investment and integration are offset by operational efficiency and share repurchases.
Performance Analysis
Doximity delivered double-digit revenue growth and strong margin expansion, underpinned by broad-based strength across customer segments and product modules. The company’s net revenue retention remained robust, especially among its largest clients, while the number of $500,000-plus subscription customers rose 17% year over year, now accounting for 84% of total revenue. Notably, free cash flow climbed sharply, aided by a favorable tax law change, and Doximity executed $122 million in share repurchases during the quarter.
Operational leverage was evident as adjusted EBITDA margin expanded despite stepped-up AI investment, and the company’s balance sheet remains strong with over $840 million in liquidity. The Pathway acquisition, though modest in near-term expense, brings a differentiated AI clinical reference corpus that is already integrated into the Doximity GPT platform. Importantly, management flagged broad-based upsell success, with workflow and newsfeed modules both seeing strong adoption, and agency partners driving >100% bookings growth in the SMB cohort.
- Customer Cohort Expansion: Large customer count rose 17%, now 84% of revenue, reflecting deeper wallet share and sticky multi-module adoption.
- Agency Portal Flywheel: Over a dozen agency partners have delivered $5 million in new business, catalyzing SMB expansion.
- AI-Driven Productivity: Internal AI use has kept headcount flat while supporting margin gains, underscoring scalable cost structure.
While the company’s guidance for the back half remains cautious due to policy uncertainty, current trends point to sustained demand and operational discipline.
Executive Commentary
"I really think AI, these AI tools in AI Suite could be our third act here. And that third act is answering the questions that doctors have when they're in front of patients... all of that, I think, will work together seamlessly and provide an opportunity that I think is in many ways as big or perhaps even bigger than our first two acts."
Jeff Tangney, CEO
"We are proud to continue to run a very profitable business with margin expansion... Our increased outlook is due to broad-based strengths across our entire business. Specific to our pharma customers, we saw a promising start to the upsell season, which we believe is due to a couple of factors. First, our expanded commercial product portfolio continues to resonate with clients."
Anna Bryson, CFO
Strategic Positioning
1. AI as the Third Act: Workflow Integration and Differentiation
Doximity’s AI suite—anchored by Scribe, GPT, and now Pathway—aims to embed the platform into the daily clinical workflow of physicians, moving beyond episodic engagement. The Pathway acquisition brings a proprietary, cross-linked medical corpus, enabling accurate and context-aware answers for complex clinical queries. Unlike generic large language models, Pathway’s evidence-weighted approach and 96% USMLE score set a new bar for clinical AI, and early integration into Doximity GPT is already driving high engagement among beta testers.
2. Commercial Platform Diversification and SMB Acceleration
The client portal and multi-module commercial offering have broadened Doximity’s reach, driving >100% bookings growth in the SMB cohort and strengthening relationships with agency partners. The portal’s real-time ROI insights and recommendations have streamlined upsell cycles, while new product modules (workflow, newsfeed, video) are seeing simultaneous adoption. This diversification de-risks the revenue base and enhances visibility, as more clients sign longer, integrated contracts with January start dates.
3. Margin Expansion and Shareholder Returns Amid Investment
Doximity is delivering margin expansion even as it ramps AI investment, with internal AI use driving productivity gains across sales, G&A, and R&D. The company has kept headcount flat while scaling revenue, and expects ongoing AI-driven efficiency to support margins long term. Share buybacks remain a priority, with dilution from new stock-based awards (tied to AI talent and Pathway) more than offset by repurchases.
4. Health System and Curative Segments Rebound
Health system customers are outperforming expectations, with strong adoption of enterprise and scheduling tools. Curative, Doximity’s physician staffing business, posted 20% growth, and management sees a multi-billion dollar locum tenens market opportunity. Both segments benefit from AI enhancements and cross-sell potential.
5. Policy and Market Visibility
Despite policy uncertainty, Doximity’s client budgets remain stable and visibility has improved, thanks to integrated contracts and portal-driven insights. Management is cautious in its outlook but notes that digital-first drug launches and stable SMB spend are providing incremental tailwinds.
Key Considerations
This quarter marks a pivotal moment as Doximity transitions from a multi-module engagement platform to an AI-native physician workflow suite. Strategic investments in proprietary AI (Pathway), commercial platform breadth, and operational leverage are reshaping both growth and risk profiles.
Key Considerations:
- AI Monetization Path: Scribe and Pathway are currently free, but management is following the dialer playbook—free to enterprise upsell—suggesting future direct subscription revenue opportunity.
- SMB and Agency Flywheel: Agency partners are now a meaningful growth engine, with $5 million in new business and a scalable model for long-tail pharma and biotech clients.
- Internal AI Productivity: AI tools are not only powering new products but also keeping operating costs in check, supporting margin expansion even as R&D and stock-based comp rise.
- Share Repurchases Offset Dilution: Buybacks are absorbing dilution from AI-driven equity grants, aligning capital returns with strategic investment.
- Balanced Customer Mix: Strength is broad-based—large pharma, SMB, health systems, and staffing—all contributing to growth and reducing concentration risk.
Risks
Policy uncertainty remains a persistent overhang, with potential regulatory changes in pharma marketing and drug pricing posing both headwind and tailwind scenarios. While AI integration is progressing rapidly, monetization of new workflow products is not imminent, and incremental costs (including stock-based comp) will pressure near-term profitability if not offset by growth. Execution risk exists in scaling Pathway and Scribe from beta to enterprise adoption, and digital health competition is intensifying.
Forward Outlook
For Q2 2026, Doximity guided to:
- Revenue of $157–158 million (15% growth at midpoint)
- Adjusted EBITDA of $87–88 million (56% margin)
For full-year 2026, management raised guidance:
- Revenue of $628–636 million (11% growth at midpoint)
- Adjusted EBITDA of $341–349 million (55% margin)
Management cited broad-based strength and a promising pharma upsell season, but continues to take a measured approach to unbooked revenue given policy uncertainty. Back half guidance reflects caution, not demand weakness, and any improvement in policy or client budgets could drive upside.
Takeaways
- AI Suite Anchors Next Growth Phase: Scribe, GPT, and Pathway integration is deepening physician engagement and sets the stage for future workflow monetization, mirroring the dialer product’s trajectory.
- Commercial Platform Diversification Reduces Risk: Agency-led SMB expansion and multi-module adoption broaden the customer base and enhance revenue visibility.
- Margin Expansion and Capital Returns Endure: Operational leverage and disciplined buybacks support shareholder value even amid stepped-up AI investment.
Conclusion
Doximity’s Q1 2026 results underscore a business model in transition, with AI-driven workflow tools and broad-based commercial momentum positioning the company for sustained growth and future monetization opportunities. Investors should watch for enterprise adoption of the AI suite and continued margin discipline as key signals of execution strength.
Industry Read-Through
Doximity’s rapid AI integration and platform diversification provide a blueprint for digital health players seeking to embed into daily provider workflows and unlock new subscription revenue streams. The company’s success with agency-led SMB expansion signals that digital-first commercialization is gaining traction in pharma, with implications for marketing mix and channel ROI across the sector. Margin expansion amid heavy AI investment highlights the leverage available to platforms that can drive both engagement and operational efficiency. Competitors and adjacent healthcare IT firms should note the accelerating shift toward AI-native, workflow-integrated solutions as table stakes for future growth.